Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
73.26 USD | -0.58% | -2.73% | -9.57% |
Mar. 18 | Gilead Sciences Receives a Shareholder Proposal from John Chevedden | CI |
Mar. 18 | Gilead Sciences Receives a Shareholder Proposal from David Bahnsen | CI |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company has a low valuation given the cash flows generated by its activity.
- This company will be of major interest to investors in search of a high dividend stock.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's enterprise value to sales, at 3.77 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.57% | 91.8B | B- | ||
+30.83% | 679B | C+ | ||
+30.96% | 589B | B | ||
+0.01% | 381B | C+ | ||
+15.18% | 314B | C+ | ||
+11.39% | 308B | B- | ||
+0.78% | 212B | B- | ||
-6.09% | 210B | A+ | ||
-2.92% | 203B | B+ | ||
-3.72% | 158B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Gilead Sciences, Inc. - Nasdaq
- Ratings Gilead Sciences, Inc.